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     Tissue hypoxia occurs where there is an imbalance between oxygen supply and consumption. 
Growing evidence from experimental and clinical studies points to the fundamental and patho-
physiologic role of hypoxia in cancer, ischemic tolerance, and stroke. Hypoxia-induced changes in 
ion homeostasis, erythropoiesis, angiogenesis, proliferation and differentiation. This review outlines 
hypoxia effect at molecular level and describes briefly hypoxia role in the physiological and 
pathological conditions. 
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1. INTRODUCTION 
     In the life of aerobic organisms, oxygen is an 
essential element. The central role of oxygen is due 
to the fact that it is the final acceptor of electrons in 
the mitochondrial respiratory chain. This allows the 
ultimate process of oxidative phosphorylation and 
the generation of cellular energy, in the form of 
adenosine triphosphate (ATP). ATP is used in most 
reactions that are necessary to maintain cellular 
viability. Under normoxia a cell continuously 
maintains a high and constant ratio of cellular 
ATP/ADP ratio in order to survive. The dependence 
of cells on a high constant ATP/ADP ratio means a 
dependence on oxygen. Therefore, a reduction of the 
normal oxygen supply (hypoxia) will have 
consequences on the cell viability [1,2]. 
    Hypoxia is encountered not only in different 
conditions including the patho-physiological 
conditions, such as atherosclerosis, obstructive sleep 
apnea, mountain sickness, ischemic diseases (stroke) 
and cancer, but also in physiological processes, such 
as embryonic development [3-6]. Different terms are 
given in the literature about the reduction of oxygen 
supply. The term hypoxemia is defined as a reduced 
oxygenation of the blood. Hypoxia is defined as a 
decrease in the oxygen supply to a level insufficient 
to maintain cellular function. Hypoxia-ischemia 
stands for the processes of hypoxia combined with 
ischemia. Ischemia differs from hypoxia in that it is 
not only a decrease in the oxygen supply; it also 
involves a reduction of the blood flow which leads to 
a decrease of nutrient supply and an accumulation of 
metabolic products, including CO2, lactic acid and 
ammonia [7-9].  
     Additionally, hypoxia response can be divided in 
different time scales, including an acute, an 
intermediate and a chronic response, and in different 
 
levels of oxygen concentration, including a moderate 
(5-8% O2) and an anoxic level (<1 O2) (normoxia is 
21% O2) [3,10,11]. The brain is regarded as the most 
hypoxia-sensitive organ because of its need for a 
high oxygen supply, whereas the skeletal muscle is 
amongst the most hypoxia-tolerant [12]. 
     The first part of this review will provide a broad 
description of responses to chronic moderate 
hypoxia. In the second part of the review, the role of 
hypoxia in the physiological and pathological 
conditions will be described.  
 
2. Sensing hypoxia 
Hypoxia orchestrates a multitude of processes of 
molecular pathway responses. However, in the 
higher organisms, the cellular oxygen sensor itself is 
unknown [1,13]. Several mechanisms have been 
proposed as to how a cell senses the lack of oxygen.  
 The traditional mechanism of hypoxia sensing 
involves a heme protein (Figure 1). This protein has 
been suggested because most proteins capable of 
binding O2 contain iron, which usually is in the 
center of a heme moiety [13].  
Hypoxia could be detected by a reversible binding of 
O2 at the heme site, which causes an allosteric shift 
in the hemoprotein, inactive (oxyform) to active 
(deoxy) form [15]. There are many kinds of heme 
containing oxygen binding proteins, but no real 
candidate has been found yet [13]. 
 Another mechanism, better known as the 
“membrane hypothesis” or “membrane model”, 
involves ion channels. It is reported that the ionic 
currents/conductance are inhibited during hypoxia in 
the O2-sensitive channels, K+- selective, Ca2+ and 
Na+ channels. 
 
   Journal of Paramedical Sciences (JPS)                   Spring 2010 Vol.1, No.2 ISSN 2008-496X 
  _____________________________________________________________________________________________________________________________________________________________________________________                  
 
  44  
 
Figure 1. The activity of a hemoprotein is determined by the presence or absence of bound oxygen [14]. 
      
     In addition, these channels are considered to 
be O2-sensitive because their modulation by O2 
occurs without known modifications in cytosolic 
variables such as pH, [Ca2+] or ATP [1,16]. 
However, how O2 interacts with the channels is 
not known. It is suggested that the channels’ 
gates are changed either by direct allosteric] 
interactions (where the sensor switches 
conformation between deoxy and oxy form) or 
by means of a mediator [1,15,17,18]. Another 
problem that occurs in this model is the fact that 
the O2-sensitive ionic currents/conductance are 
either inhibited or increased in the same channel 
type in different cells [1,18].  
     The mitochondrion itself has been suggested 
to be the site of hypoxia sensing. This is based 
on the fact that the mitochondria binds O2 and 
represents the primary site of oxygen 
consumption in the cell [19]. Furthermore,  
experiments of agents mimicking hypoxia have 
shown an inhibition of mitochondrial function 
(oxidative phoshorylation) [20]. The main 
problem in “the mitochondrial hypothesis” lies 
in how the mitochondria can detect differences 
in the O2 supply [15]. But the mitochondrial 
involvement is an attractive proposal since it 
provides a link between O2 ensing and 
metabolism. 
     However, the search for an oxygen sensor is 
wide open and none of the different suggested 
mechanisms can be excluded. 
3. Responses to chronic moderate hypoxia 
     Under chronic moderate hypoxia 
multicellular organisms trigger a multitude of 
cellular responses in order to survive and 
maintain the oxygen homeostasis in function of 
time (Figure 2). Here the most important 




Figure 2. Main responses to hypoxia 
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3.1. Ion homeostasis 
     The acute response to hypoxia is believed 
to be significant disturbances of the ionic 
homeostasis. It is suggested that the ion 
channels are some of the first proteins to sense 
the low oxygen level, as mentioned earlier 
(hypotheses of oxygen sensing). The obvious 
choice of the ion channels comes from the fact 
that cells spend much of their ATP production 
to maintain the ionic gradient. Under 
normoxic condition, it is estimated that up to 
60% of the ATP production is used by the ion-
motive ATPases, such as the Na+/K+ ATPase 
and Ca2+-ATPase [21].  
     During hypoxia a decrease in the 
intracellular ATP/ADP ratios causes an 
enhanced cellular K+ efflux and Na+ and Ca2+ 
influx [22]. With the decreased activity of the 
K+ channels, the membrane depolarizes and 
activates the voltage-gated Ca2+ channels, 
causing an increase in the concentration of 
intracellular Ca2+. The overload of intracellular 
Ca2+ causes among other things (1) changes in 
the mitochondrial metabolisms, (2) an 
activation of lipases and proteases which leads 
to membrane damage and a release of free 
fatty acids and proteins, (3) an activation of 
endonuclease and (4) a generation of reactive 
oxygen species (ROS) [22-25]. The bridge 
between the acute (depolarization) and chronic 
(changes in gene and protein expression) 
responses to hypoxia is believed to be this 
increase in the intracellular Ca2+. Under 
chronic hypoxia, changes in the gene 
expression are regulated by the oxygen-
regulated transcription factor HIF-1 (see 3.2). 
The key protein, which links the acute and 
chronic responses, is believed to be the CaM 
kinase II. The increase in the intracellular Ca2+ 
levels, and its subsequence binding to 
Calmodulin, leads to an activation of CaM 
kinase II, which phosphorylates the co-
activator (p300) of the HIF-1 complex. This 
phosphorylation induces the HIF-1 
transcriptional activity [26]. 
     Because of the limited information about 
the effect of hypoxia on Na+, the exact 
contribution of Na+ under hypoxia is not 
known [27]. It is proposed that the increased 
intracellular Na+ concentration during hypoxia 
contributes to the increase in the intracellular 
Ca2+ concentration by reversing the Na+/Ca2+ 
exchanger [28,29]. However, under chronic 
hypoxia, a decreased and an increased 
expression of the Na+ channels have been 
reported [30].  
 
3.2. Hypoxia-inducible factors (HIFs) 
      While triggering ion channels is an acute     
response, at the molecular level, the hronic 
response to hypoxia involves changes in the 
gene expression [14]. The essential step in this 
process is an activation and stabilization of the 
hypoxia-inducible factors (HIFs) [31]. HIFs 
are universally used as transcriptional 
regulators, which are “turned on” by chronic 
hypoxia. The HIF family comprises three 
members, HIF-1, HIF-2 and HIF-3, with the 
function of HIF-3 poorly understood. HIF-1 is 
ubiquitously expressed, whereas HIF-2 is only 
expressed in endothelial cells and in the 
kidney, heart, lungs and small intestine [32-
34]. HIF-1 transcriptional complex was the 
first transcription factor to be discovered. It 
binds to DNA at hypoxia response elements 
(HRE) in the enhancer or promoter region of 
target genes [35]. HIF-1 complex is a 
heterodimer consisting of an inducible O2-
regulated HIF-1α subunit and a constitutively 
expressed HIF-1β [31].  
The HIF-1 activity is tightly regulated, (for 
reviews see: [4,13,36-39]). During normoxia, 
HIF-1α is subjected to multiple modes of post-
translational modifications (Figure 3). HIF-1α 
is hydroxylated on two proline residues in the 
oxygen-dependent degradation domain by the 
oxygen-sensitive prolyl hydroxylase domain 
(PHD) proteins. This modification leads to an 
interaction with the ubiquitin E3-containing 
ligase von Hippel Lindau complex (pVHL), 
which targets HIF-1α by attaching 
polyubiquitin chains for proteosomal 
degradation. Furthermore, HIF-1α is 
hydroxylated by another oxygen-sensitive 
enzyme, Factor Inhibiting HIF-1 (FIH-1), on 
the asparagine residue in the C-terminal 
transcriptional activation domain to prevent 
interaction with the transcriptional co-activator 
CBP/p300, and thereby represses the 
transactivational activity of HIF-1. These post-
translational modifications keep HIF-1 in an 
unstable and inactive state. The half-life time 
of HIF-1α is only a few minutes (<5 minutes) 
under normoxia [1]. During hypoxia the PHDs 
and the FIH-1 become inactive. The lack of 
hydroxylation results in stable HIF-1α, which 
will dimerize with HIF-1β. The heterodimer is 
then nuclear translocated and binds to the 
HRE on the target genes. Since FIH-1 is 
inactive, the co-activator CBP/p300 is 
recruited for activation of the transcription. 
 It should be mentioned that the mechanism 
responsible for the post-translational     
modifications of HIF-1α is not known. But it 
is suggested that PHD might be involved in
   Journal of Paramedical Sciences (JPS)                   Spring 2010 Vol.1, No.2 ISSN 2008-496X 
  _____________________________________________________________________________________________________________________________________________________________________________________                  
 
  46  
this regulation [40]. 
     It is believed that approximately 1-5% of  
the genome is transcriptionally regulated by 
hypoxia and many of these genes are known to 
be regulated by HIFs [41]. So far, more than 
200 target genes have been reported to be 
induced by the HIF complex. These genes are 
involved in many different biological 
processes, including erythropoiesis, 
angiogenesis, proliferation, energy metabolism 
or apoptosis [38,39,42]. However, the gene 
expression pattern in response to the HIF 
activation is cell-specific. Hence, the 
protective response by the HIF activation in 
one cell lineage may not be evident in other 
cell types [42]. 
 
 
Figure 3.  Regulation of HIF-1α during normoxia and hypoxia. [37]. 
 
 
3. 3. Erythropoiesis 
     In response to chronic hypoxia, the 
capacity of red blood cells to transport oxygen 
is up-regulated by the expression of genes 
involved in erythropoiesis. Most notably, the 
erythropoietin (EPO) gene is increased by 
hypoxia, which is required for the formation of 
red blood cells. An increase of the number of 
the red blood cells enhances the delivery of 
oxygen to tissues [43]. Furthermore, iron is 
required for heme formation and is the most 
limiting factor in erythropoiesis. Hypoxia 
increases the expression of the iron-
metabolizing genes, including transferrin, 
transferrin receptor and ferroxidase. The 
increase of these genes supports the iron 
supply to the erythroid tissues [44]. It is well 
established that the expression of genes 
involved in the erythropoiesis is regulated by 
HIF-1. Indeed, oxygen-regulated EPO, 
transferring receptor and ferroxidase 
expression have been reported to be controlled 
by HIF-1 [13, 45]. 
 
3.4. Angiogenesis 
     Chronic hypoxia induces angiogenesis. 
Angiogenesis is the process by which new 
blood vessels develop from existing 
vasculature. Angiogenesis can be defined as a 
multistep process, which involves endothelial 
cell activation, increased blood vessel 
permeability, and local rearrangement of the 
basal membrane and extracellular matrix. 
Angiogenesis provides a principle mechanism 
for the maintenance of an adequate blood flow 
to areas of insufficient oxygen supply [46]. 
However, angiogenesis requires production 
and secretion of the so-called angiogenesis 
factors, such as vascular endothelial growth 
factor (VEGF), platelet-derived growth factor 
(PFGF), fibroblast growth factor (FGF), and 
interleukin-8 [47]. In keeping with the central 
role of HIFs in responses to chronic hypoxia, 
it is shown that HIF-1 directly activates the 
expression genes involved in angiogenesis, 
including VEGF, VEGF receptors FLT-1, 
transforming growth factor-β3 (TGF- β3), 
angiopoietins and genes involved in matrix 
metabolism [48,49]. The most notable and 
characteristic angiogenesis factor induced by 
HIF-1 is VEGF. It is essential for the 
proliferation and migration of vascular 
endothelial cells, thereby enabling the 
formation of new blood vessels [50]. Several 
studies using both HIF mutant cell lines and 
murine model systems have shown that HIF 
signaling is required for the regulation of 
VEGF. However, the relative contribution of 
individual HIF family members in the 
induction of VEGF expression and 
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angiogenesis process is controversial. The 
individual contributions appear to be cell-type 
dependent [51, 52]. However, blood flow 
under pathophysiological conditions is 
controlled by modulations of the vascular tone 
through a production of NO (inducible nitric 
oxide synthase), CO (heme oxygenase 1), 
endothelin 1, adrenomedullin, or an activation 
of the α1B-adrenergic receptor, all of which 
involve HIF-1 target genes, too. Therefore, 
HIF mediates angiogenesis by mechanisms, 
far more complex than the simple VEFG 
induction [45]. 
 
3. 5. Proliferation 
     Chronic hypoxia induces expressions of the 
various growth factors that are known to 
promote cell proliferation. This proliferation is 
normally involved in initiating cell migration 
and regeneration after acute or chronic 
hypoxia damage [53]. Several growth factors, 
most notably insulin-like growth factor 2 
(IGF-2) and transforming growth factor-α, are 
HIF-1 target genes. Binding of these growth 
factors to their cognate receptors, the insulin-
like growth factor 1 receptor (IGFIR) and 
epidermal growth factor receptor (EGFR) 
respectively, activates signal transduction 
pathways that lead to both HIF-1α expression 
and to cell proliferation/survival [48]. 
Furthermore, it is shown that the p42/p44 
mitogen activated protein kinase (MAPK), 
which regulates cell proliferation in response 
to extracellular growth factors, phosphorylate 
HIF-1α and activate transcription of HIF-1 
target genes [53]. 
 In addition, phosphatidylinositol 3-OH kinase 
(PI3K) activity is also increased in some cell 
 types under hypoxic conditions. PI3K is one 
of the key downstream mediators of many 
tyrosine kinase signaling pathways involved in 
regulating cell proliferation and suppression of 
apoptosis [54].       
 
3.6. Differentiation 
     Accumulating evidence suggests that 
hypoxia promotes cell differentiation in a 
variety of cell types. A clear link has been 
demonstrated between hypoxia, HIFs and 
molecules that are critical for the regulation of 
the differentiation of cells, including Notch, 
Oct-4 and MYC [55]. Recently, it was 
observed that hypoxia directly influences the 
Notch signalling pathway activity in the cell 
differentiation process [56]. Notch mediates 
cell-cell signalling between adjacent cells that 
express Notch receptors (Notch 1-4) and 
Notch ligands (Delta, Serrate and Lag-2). In 
response to ligand presentation from 
neighbouring cells, Notch receptors undergo 
proteolytic activations to liberate the Notch 
intracellular domain (ICD). Subsequently, ICD 
forms a complex with DNA binding protein 
CSL and co-activators, such as p300/CBP, to 
activate Notch target genes. These in turn 
negatively regulate the expression or activity 
of the differentiation factors [57]. HIF-1α has 
been shown to associate physically with ICD, 
promoting its stability. A model is proposed in 
which HIF-1α interacts with the Notch-CSL 
transcriptional complexes at Notch-responsive 
promoters in hypoxic cells to control the 
differentiation status [56]. However, the 
protein “bridging” direct interaction between 
HIF-1α and ICD is unknown [58]. Other 
molecular pathways underpinning the hypoxic 
control of the cell differentiation process 
involves OCT4 and MYC transcription factors 
which are directly regulated by HIF-2α [55, 
59]. However, how HIF-2α leads to the 
activation of these transcription factors are 
poorly understood. It is shown that when the 
Oct-4 locus is an open configuration, HIF-2 
complex binds and induces its expression [60]. 
In the case of MYC, it is postulated that HIF-
2α directly interacts with MYC-MYC-
associated protein X (MAX) complex which 
leads to a stabilization of this complex and a 
transcriptional activation [59].  
     A search in the literature shows that a 
significant amount of work is performed to 
show that hypoxia plays an important role in 
the cell differentiation process. However, the 
molecular pathways involved in this process 
are poorly understood [61].  
 
3.7. Energy metabolism 
     A key adaptive response to chronic hypoxia 
is a switch from oxidative phosphorylation to 
anaerobic glycolysis. Under normoxic 
conditions, cell energy in the form of ATP is 
mainly generated through the oxidative 
metabolism of carbohydrates, fats and amino 
acids. During hypoxia, ATP generation by 
oxidative phosphorylation is arrested. This 
will stimulate glycolysis with an increase in 
glucose consumption and lactate production 
[62,63]. The switch of the respiratory pathway 
to anaerobic glycolysis leads to a significant 
reduction of the ATP/ADP ratios. Because of 
the reduced energy supply, the hypoxic cells 
will further response by shutting down the 
non-essential energy consuming mechanisms, 
such as protein synthesis, and relocate the 
energy to more critical functions, such as the 
maintenance of the ion homeostasis and 
membrane potential [12,21]. Additionally, the 
glucose metabolism is regulated by the HIF 
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pathway. HIF-1 complex induces virtually all 
genes encoding glucose transports and 
glycolytic enzymes [64,65]. It is also 
suggested that HIF-1 represses mitochondrial 
respiration. This occurs by an induction of 
pyruvate dehydrogenase kinase 1 that inhibits 
pyruvate dehydrogenase, the enzyme that 
converts pyruvate to acetyl-CoA for entry to 
the Krebs cycle [66]. In addition, it is 
postulated that HIF-1 induces expressions of 
some proteins in the mitochondria for a more 
efficient transfer of electrons to oxygen [3]. A 
switch in the metabolic pathway to anaerobic 
glycolysis leads to an increase in the glucose 
consumption. The largest store of glucose 
equivalents is glycogen.  
Indeed, it is observed that during hypoxia, 
glycogenolysis is induced [67].  
     Recently another pathway has been 
suggested to play an important role during 
hypoxia by regulating the energy metabolism: 
the AMP-activated protein kinase (AMPK) 
pathway [20,68]. AMPK is regarded as an 
energy-sensing enzyme. It is a heterotrimeric 
complex composed of a catalytic α-subunit 
and regulatory β- and γ-subunits [69,70]. As 
mentioned earlier, hypoxia results in a fall in 
the cellular energy status. As a consequence, 
the enzyme adenylate kinase will catalyze the 
reaction: 2 ADP ↔ AMP + ATP in order to 
maintain cellular ATP levels. This will results 
in a large increase in the AMP levels. AMP 
activates the AMPK complex in three 
independent ways: 1) allosteric regulation via 
the γ-subunit; 2) promotion of phoshorylation 
of AMPK by one or more upstream kinases; 
and 3) inhibition of dephosphorylation of 
AMPK [69].  
 
 
Figure 4. Key processes of the energy metabolisms that 
are regulated by AMPK. The multiple effects of AMPK 
regulate some of these processes [69] 
 
Furthermore, the AMPK complex can be 
activated by a rise in intracellular Ca2+, which 
is seen in hypoxia, through phosphorylation by 
a Ca2+-dependent kinase activity [70,71]. The 
activated AMPK complex has a lot of 
downstream targets in cells or tissues [2]. In 
general, stimulation of the AMPK pathway 
promotes catabolic pathways that generate 
ATP, in order to maintain the ATP supply, 
while switching off non-essential ATP 
consuming (anabolic) pathways. This is done 
by direct phosphorylation of the Regulatory 
proteins involved in the process, and by an 
indirect effect on gene expressions [72]. 
Figure 4 shows some of the key effects of 
AMPK on the energy metabolism.  
 
3.8. Acidosis 
 A switch from aerobic to anaerobic glycolysis 
decreases the consumption of H+ due to the 
lowered production of ATP (by oxidative 
phosphorylation) on the one hand, and a 
generation of more H+ by other metabolic 
reactions, such as the ATPases reaction (ATP 
+ H2O ↔ ADP + Pi + H+) on the other hand 
[62]. During hypoxia, the cellular pH 
homeostasis is disturbed [9]. A gradual 
decrease in both extracellular and intracellular 
pH is observed [73]. Studies have shown an 
approximately drop of 0.8-1.2 pH units [74]. It 
is postulated that acidosis might be protective 
to hypoxic cells. Acidosis can slow down 
some of the enzymatic processes, reduce 
energy consumption and ROS production [9].  
Additionally, acidosis inhibits ion fluxes 
through cellular membrane channels, thereby 
reducing the energy required for maintaining 
ion gradients across the plasma membrane 
[75]. Hypoxia-induced acidosis plays an 
important role in the stabilization of HIF-1α. 
It is shown that a decrease in pH triggers re-
localization of the von Hippel-Lindau protein 
(pVHL) from diffuse nuclear-cytoplasmic 
pattern to nucleoli. This nucleolar 
sequestration of pVHL stabilizes HIF-1α by 
not ubiquitinylating the HIF-1α for protesomal 
degradation [76]. HIF-1 complex contributes 
to the cells’ surviving the metabolic acidosis 
by enhancing several genes of membrane 
located transporters (e.g. the H+/lactate 
monocarboxylate), exchangers (e.g. the 
Na+/H+ exchanger), pumps and ecto-enzymes 
(e.g. carbonic anhydrase IX) [3]. 
 
3.9. Reactive oxygen species (ROS) 
     The term reactive oxygen species (ROS) 
encompasses wide range of molecules. Free 
radicals are chemical species containing one or 
more unpaired electrons. The unpaired 
electrons of oxygen react to form partially 
reduced highly reactive species that are 
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classified as ROS, including superoxide (O2), 
hydrogen peroxide (H2O2), hydroxyl radical, 
and peroxynitrite. Under normoxia, ROS can 
be generated at several cell sites and 
organelles, though the major site of ROS 
production is the mitochondrial electron 
transfer chain (ETC) [77]. It is estimated that 
under normoxia up to 2% of the electron flow 
on the ETC leads to ROS production [37]. 
ROS has also been suggested to be an essential 
participant in cell signaling, acting as a second 
messenger [78-80]. Under hypoxia, it is 
unclear how ROS is formed. Therefore, it has 
become the most debated subject of cells or 
tissues exposed to hypoxia. Controversial 
results of the generation of ROS during 
hypoxia have been published. Investigators 
have observed both decreases and increases of 
ROS levels in the cells or tissues exposed to 
hypoxia [37,81,82].  Inconsistencies in studies 
on the direction and degree of ROS level 
production come from the differences in cell 
types and sub-cellular compartments 
examined. Additionally, there are no direct 
methods for measuring intracellular ROS 
levels [83]. However, it seems that it is 
accepted that exposure of cells to a chronic 
moderate hypoxia leads to a relative increase 
in ROS generation [84]. Increases in cellular 
ROS levels are regarded as toxic. Cells 
possess several antioxidant systems, such as 
the enzyme superoxide dismutase and non-
enzymatic antioxidant NADPH-coupled 
reactions, to protect themselves from these 
toxic species [85,86]. If one accepts that the 
increase of the ROS levels during hypoxia 
comes from the mitochondria site, it is 
postulated that it plays an important role in 
HIF-regulation [19,37,83]. It is shown that 
HIF-1 activation directly correlates with 
changes in ROS [87]. But it is not known how 
mitochondrial ROS regulate HIF-1 stability. It 
is proposed that the PHDs might be the key 
element. It is suggested that ROS triggers an 
unknown signal transduction cascade, which 
results in post-translational modifications of 
PHDs. These unknown post-translational 
modifications will make these proteins 
inactive. Inactivation of the PHDs leads to a 
stabilization of HIF-1α [19,68,83]. 
 
3.10. Cell death     
      Paradoxically, cell adaptation to hypoxia 
leads not only to cell proliferation/survival but 
also to cell death in some circumstances. 
When the protective adaptive mechanism, 
initiated by HIF-1 is not sufficient, cell death 
occurs [33]. Hypoxia induces cell death by a 
number of HIF-1-mediated and –independent 
pathways [53]. It is demonstrated that chronic 
moderate hypoxia alone is not sufficient to 
cause cell death [88,89]. A cell death requires 
a combination of factors/events, such as an 
increased level of Ca2+, a generation of ROS, a 
change in the cellular energy levels and 
acidosis etc. [9,88,90-92]. There are different 
forms of cell death, including necrosis, 
apoptosis and autophagy. There are extensive 
reviews about these cell death mechanisms, 
which will not be discussed here [90,91,93].  
Necrosis is defined as a passive form of cell 
death, since it can occur in absence of ATP 
[94]. It is believed to be caused by a disruption 
of cellular ionic gradients in association with a 
reduced ATP/ADP ratio [95]. In contrast, 
apoptosis is an energy dependent and delayed 
form of cell death that occurs as the result of 
an activation of a genetic program [89,96]. 
The autophagy has been described as an 
alternative form of programmed cell death, a 
non-apoptotic form. During this process, the 
cell “eats itself” [93]. 
     When and which form of cell death takes 
place during the hypoxic condition is debated. 
It is suggested that an increase of ionic Ca2+ 
leads to a rapid or a slow consumption of 
ATP. It is postulated that a rapid use of ATP 
leads to necrosis, whereas a slow use of ATP 
leads to apoptosis [8,97]. Furthermore, it has 
recently been suggested that the autophagy 
form of cell death can be involved in hypoxia. 
This form of cell death has been postulated to 
represent an early survival mechanism. In this 
strategy, cells switch to a catabolic metabolic 
program in which cellular constituents are 
degraded for energy production [3]. 
     HIF-1 contribution to cell death is also 
debated. It is discussed that HIF-1 can either 
be anti-apoptotic or pro-apoptotic, but it 
depends on the cell type and experimental 
conditions [33, 94]. Under chronic hypoxia, 
HIF-1 induces apoptosis. It is shown that HIF-
1 increases the expression of various pro-
apoptotic members of the BCL-2 (B-cell 
lymphoma-2) family [11,94,98]. The BCL-2 
family is separated in three classes: the first 
class inhibits apoptosis, the second class 
promotes apoptosis, and the third class can 
bind and regulate the anti-apoptotic BCL-2 
proteins to promote apoptosis [99]. HIF-1 
complex has been shown to specifically induce 
the second class members of the BCL-2 family 
[98,100]. These classes lead to 
permeabilization of the outer mitochondrial 
and the subsequent release of apoptogenic 
molecules, such as cytochrome c, which leads 
to an activation of the caspase proteins. 
Caspases, which are cysteinyl aspartate 
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proteases, in turn cleave a series of substrates, 
activate DNases and orchestrate the demolition 
of the cell [99].  
     Furthermore, chronic hypoxia induces the 
stabilization of tumor suppressor p53 protein 
[101,102]. Traditionally, p53 protein controls 
cellular homeostasis by affecting cell cycle 
progression and apoptosis. Under normoxia, 
p53 has a very short half-life and the protein is 
often at an undetectable level. Cell exposure to 
stress such as DNA damage or chronic 
hypoxia, leads to a stabilization of p53. As a 
consequence, p53 becomes activated as a 
transcription factor and promotes transcription 
of genes involved in cell cycle regulation, 
apoptotic event etc. [103]. It is argued that a 
direct interaction between p53 and HIF-1α 
leads to p53 stabilization, which results in an 
inhibition of HIF-1 dependent transcription 
[33,104,105]. Furthermore, it is proposed that 
p53 leads to a targeting of HIF-1α for 
ubiquitination and subsequent proteasomal 
degradation [106]. However, a search in the 
literature shows that a unifying picture 
concerning hypoxia and cell death is lacking 
and how cells balance between adaptation and 
cell death is still an unanswered question. 
 
4. Physological and Pathological responses 
to hypoxia 
Hypoxia has been implicated in a range of 
pathological and physiological conditions, and 
it can be harmful or beneficial, depending on 
the circumstances. In the following text the 
most well known hypoxic conditions will be 
described. 
 
4.1. Detection of hypoxia 
Chronic hypoxia is a strong prognostic factor 
for the outcome of various diseases. Currently, 
the use of 2-nitromidazole drugs that 
specifically bind to hypoxic cells has been 
largely advocated, pimonidazole and EF5 
being the most well known [107]. Reductive 
enzymes metabolize these drugs in the 
presence of oxygen, while when oxygen is 
absent, the extra electrons are not removed, 
and the drugs are converted to highly reactive 
free radical molecules that covalently bind to 
protein and DNA. The drug-protein adduct can 
then be detected by specific antibodies 
[5,108]. However, the disadvantage of these 
drugs is that they have to be administered 
before sampling the tissue. Therefore, the 
search for possible surrogate markers for 
hypoxia is still growing. 
 
4.2. Hypoxia preconditioning/ Ischaemic 
   tolerance 
     Although hypoxia is correlated with 
pathological conditions, in the recent years it 
has been used for preconditioning stimuli. 
Preconditioning is defined as a stressful but 
non-damaging stimulus to cells, tissues or 
organisms to promote a transient adaptive 
response, so that injury resulting from 
subsequent exposure to a harmful stimulus is 
reduced [109].  
     Hypoxic preconditioning, or hypoxia-
induced tolerance, refers to a brief period of 
hypoxia that protects against an otherwise 
lethal insult (for example, stroke) minutes, 
hours or days later. Hypoxic preconditioning 
protects the brain, heart and retina against 
several types of injury, including ischemia 
[110]. It is proposed that the protective 
response induced by hypoxic preconditioning 
is due, at least in part, to hypoxic induction of 
HIF isoforms and HIF isoforms target genes. 
Indeed, several studies have shown systemic 
hypoxia, which produced hypoxic 
preconditioning and protected the brain against 
ischemia, increased the levels of HIF-1α in 
neonatal and adult rodent brains [111,112]. 
Additionally, hypoxic preconditioning can also 
be achieved by known chemical inducers of 
HIF-1α such as CoCl2 and desferrioxamine, 
suggesting that the preconditioning 
phenomenon is mainly mediated by HIF-
activity [113]. Although, hypoxia leads to an 
increase level of HIF, it is probably the HIF 
target genes that provide the protection against 
subsequent ischemia and other types of injury. 
Indeed, induction of some of these genes 
products, such as EPO and VEGF, has been 
shown to protect the brain against ischemia on 
their own. In particular, it is shown that EPO 
both protects the brain against ischemia and 
produce an EPO-mediated preconditioning 
[114, 115]. Furthermore, it is reported that an 
overexpression of glucose transporter 1, which 
is important for the glucose metabolism, 
protects cells in vitro and in vivo against 
ischemia and other types of injury [116]. 
However, hypoxic preconditioning is more 
complex than the involvement of the 
transcription factor HIF. Indeed, studies have 
shown that other transcription factors and their 
target gene products might participate in this 
response, including activating protein 1 (AP1), 
the cyclic AMP-response-element-
binding(CREB), nuclear factor-κB (NF-κB), 
early growth response 1 and the redox-
regulated transcriptional activator SP1 [117-
120]. Moreover, preconditioning can also be 
induced by hyperoxia, oxidative stress, 
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inflammatory cytokines, anaesthetics and 
metabolic inhibitors [109].  
     Nonetheless, the best current research 
strategy in order to obtain preconditioning 
aims to mimic the hypoxic response by 
increasing HIF-1 activity [121]. Induction of 
HIF-1 could occur either specifically, with 
targeted inducers, through gene therapy or 
through the action of hypoxia mimetics [122].    
 
4.3. Stroke/Cerebral Ischemia and the 
potential role of neuroglobin 
     Stroke (hypoxia-ischemia) occurs when 
cerebral blood flow to the brain is interrupted. 
It restricts the delivery of substrates, 
particularly oxygen and glucose, and impairs 
the energetics required to maintain ionic 
gradients. With energy failure, membrane 
potential is lost and neurons and glia 
depolarize. Subsequently, the voltage-
dependent Ca2+ channels become activated and 
cause accumulation of intra-neuronal free Ca2+ 
[123]. A prolonged elevation of intracellular 
Ca2+ leads to the catabolic process of vital 
molecules and irreversible death of neuronal 
cells through multiple mechanisms that 
involve the activation of Ca2+-dependent 
effector proteins, such as calpains, 
endonucleases and caspases [124]. 
Furthermore, ROS are produced by the Ca2+-
dependent enzymes, such as nitric-oxide 
synthase, phospholipase A2 and 
cyclooxygenase [125,126]. The important role 
of ROS in cell damage associated with stroke 
is understood by the fact that even delayed 
treatment with free-radical scavengers can be 
effective in experimental ischemia [127]. In 
the initial phase of a stroke, an induction of 
HIF-1 is reported. However, this induction 
seems to be by a hypoxia-independent 
pathway, e.g. via cytokines [110,121].  
Furthermore, HIF-1 is a marker for chronic 
hypoxia, where failure of ion homeostasis and 
an increase in intracellular Ca2+ concentration 
is an acute hypoxia effect [53]. Therefore, the 
induction of HIF-1 during stroke remains 
unclear. Nevertheless, the disturbance of ion 
homeostasis plays an important role in the 
pathogenic of the stroke; other mechanisms, 
such as inflammation and peri-infarct 
depolarizations, are involved in the complex 
sequence of the pathological events that 
evolve over time and space [126]. 
     The brain also activates neuroprotective 
mechanisms in an attempt to counteract the 
damaging effects of excitotoxicity [128]. By 
administrating EF5, a hypoxia marker (see 
4.1), in an experimental animal model, it is 
shown that the brain is hypoxic during the first 
few hours of recovery, but the tissue is no 
longer hypoxic after 2 days [129]. This 
hypoxic period is believed to play an 
important role in protecting the brain cells 
from further damage. It is postulated that 
hypoxia induced HIF-1 levels lead to 
proportional increases in the HIF-1 target 
genes product during recovery [130]. It is well 
documented that during recovery, HIF-1 target 
genes, such as EPO, VEGF and IGF 2, 
involved in the erythropoiesis, angiogenesis 
and proliferation processes respectively, are 
over-expressed [110]. Additionally, it is 
suggested that HIF might be important in 
affecting cell survival and recovery through a 
regulation of the cellular antioxidant capacity. 
It is believed that the most damaging effect 
during recovery (reperfusion) is caused by an 
increased generation of ROS [42,131].  
     Moreover, neuroglobin (Ngb), a recently 
discovered protein, is suggested to be the key 
mediator of hypoxic-ischemic injury-repair 
coupling in the brain [132]. Ngb is a 
monomeric heme-protein, which binds oxygen 
reversibly, and is preferentially expressed in 
the neurons of the central and peripheral 
nervous systems (CNS, PNS) [133]. The 
intracellular globins play an important role in 
oxygen homeostasis of the animal cells, e.g. 
myoglobin facilitates oxygen diffusion to the 
mitochondria and stores oxygen for short or 
long term periods of hypoxia [134]. We have 
recently shown that Ngb is upregulated in the 
human neuroblastoam cell line under hypoxic 
condition [135]. Additionally, another group 
has shown that Ngb is upregulated in mice 
brain exposed to hypoxia-ischemia condition 
[136]. However, we and the other group were 
not able to show statistically significant 
upreglulation of Ngb in mice brain under 
hypoxic condition [137, 138]. Therefore, 
upregulation of Ngb in mice brain under 
hypoxic condition remains an open question. 
The mechanism for hypoxic induction of Ngb 
is unknown. However, both HIF-dependent 
and independent mechanisms of induction has 
been suggested [132]. It is postulated that Ngb 
protects neurons from hypoxic and ischemic 
cell death [139]. However, since Ngb is a 
relatively newcomer, it remains unknown how 
Ngb protects neurons [140]. Several 
neuroprotective mechanisms have been 
proposed for Ngb. It is suggested that Ngb 
might have an Mb-like function in the oxygen 
supply to the respiratory chain, either by 
facilitating oxygen diffusion or by providing a 
short term oxygen store [141]. We suggest that 
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Ngb can function as a ROS scavenger during 
oxidative injury. Our conclusion is based on 
firstly, an increase survival of cell over-
expression Ngb under H2O2 stress and 
secondly, the observation that in eyes a 
negative correlation of Ngb and H2O2 levels in 
hypoxia/reoxygenation studies is present [137, 
142].  Additionally, other studies have shown 
Ngb is an efficient scavenger of NO. and 
peroxynitrite [143,144]. Furthermore, it has 
been suggested that Ngb can interact with Rho 
GTPases as a GDP-dissociation inhibitor 
(GDI). Rho GTPases are GDP-bound and 
maintained inactive in the cytosol, complexed 
with a GDI. Activation of Rho GTPases 
requires GDI dissociation, replacement of 
GDP with GTP, and intracellular translocation 
of GTPases from the cytoplasma to the plasma 
membrane. Binding of Ngb to Rho GTpases 
keep this protein in the inactive form [145]. 
Recently, it has been demonstrated that this 
interaction leads to inhibition of death 
signaling [139]. Additionally, it is suggested 
that Ngb inhibits apoptosis by inactivating 
Cytochrome c (Cyt c). It is shown that Ngb 
ferrous (Fe2+) can reduce Cyt c ferric (Fe3+), 
thereby inactivating Cyt c in the apoptotic 
pathway [146].  
     Based on the current observation that Ngb 
expression is induced by neuronal hypoxia, 
cerebral ischemia, ischemia/reperfusion, and 
probably other neurodegenerative diseases, it 
is suggested that Ngb has the potential to be a 
neuroprotective molecule [132].  
 
4.4. Hypoxia and cancer 
     It was more than 50 years ago that it was 
first reported that human tumors grew under a 
condition which was termed “chronic 
hypoxia” [147]. It is described that hypoxia 
contributes to selecting cancer cells resistant to 
apoptosis and mediates resistance to 
chemotherapy and radiotherapy [148].                   
Therefore, a correction of hypoxia before 
radiation therapy is routine, by using blood 
transfusion to increase the haemoglobin 
concentration in patients, which results in a 
better response to the therapy [149]. 
Nowadays, hypoxia in human cancers, such as 
the head and neck, cervical or breast cancer, is 
associated with increased metastasis and poor 
survival in patients [150, 151]. As earlier 
mentioned, cells undergo a variety of 
responses to the chronic hypoxic condition, 
which involves different pathways. The 
earliest pathway was noted 70 years ago: 
cancer cells shift from oxidative 
phosphorylation to anaerobic glycolysis. This 
process is known as the Warburg effect and 
involves a decreased mitochondrial respiration 
and an increased lactate production, even in 
the presence of oxygen [152]. Furthermore, it 
has been known for a long time that 
tumorigenesis involves multiple mechanisms, 
including angiogenesis, proliferation, 
metastasis, differentiation [153, 154]. 
However, a better understanding of the 
regulation of the multiple steps in 
tumorigenesis was first recognized in the early 
1990s when HIF-1 was identified. Today, it is 
well established that HIFs play an important 
role in tumour progression. Studies have 
reported that HIF-1α, HIF-2α and HIF-3 α are 
overexpressed in human cancers, and that the 
level of expression is correlated with 
tumorigenesis and patient mortality [155-157]. 
Furthermore, in support of HIF-1’s role in 
tumour progression, it is reported that genetic 
or pharmacological inhibition of HIF-1 in 
animal model systems manifests a decrease in 
tumorigenesis and an increase in survival [158, 
159]. Additionally, recent studies have 
provided evidence indicating that HIF-1 
mediates resistance to chemotherapy and 
radiation [160,161]. Therefore, with a growing 
understanding of the HIF-1 pathway, the 
regulation of its transcriptional activity has 
become an attractive goal for therapeutic 
targeting in cancer. Currently, different 
approaches have been used to inhibit HIF-1α 
gene transcription: through inhibition of the 
ability of HIF-1α to interact with proteins that 
modulate its activity, or through inhibition of 
signal transduction pathways [162]. There are 
several approved therapeutic agents reported 
which are capable of inhibit HIF-1 activity, 
including Trastuzumab (Herceptin), Imatinib 
(Glivec), Camptothecin. Although, the 
anticancer effect of these agents might be due, 
in part, to their inhibition of HIF-1, none of 
these drugs specifically target HIF-1. The lack 
of selectivity increases the difficulty in 
correlating molecular and clinical responses in 
patients, but it does not disqualify these drugs 
as potential anticancer agents [155].  
 
4.5. Hypoxia and cancer stem cell  
     In recent years, it has been observed that 
hypoxia plays an important role in the 
differentiation of stem cells to cancer stem 
cells. Stem cells are undifferentiated cells, 
generally characterized by their functional 
capacity to both self-renew and to generate a 
large number of differentiated progeny cells 
[163]. Because of their exceptional properties, 
stem cells have the potential to be used for 
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developmental biology, drug screening, 
functional genomics applications, and 
regenerative medicine. Stem cells reside in 
specialized cellular contexts called stem-cell 
niches, which are defined as particular 
locations or microenvironments that provide 
the signals and physical support to maintain 
stem cells. Cancer stem cells are cancer-
initiating cells that can self-renew and 
generate distinct cell types. These cells are 
capable of indefinite self-renewal and can give 
rise to rapidly dividing transit amplifying cells 
that have a limited capacity for self-renewal 
and whose progeny differentiate to produce 
the bulk of the tumor [164, 165]. The finding 
that many cancers are maintained by a small 
population of stem cells has extremely 
important implications for both understanding 
and treating cancer. A major question is how 
these stem cells arise. The source of cancer 
stem cells is not entirely clear and may differ 
depending on the specific disease. They can 
arise from normal stem cells that have 
sustained a mutation to make them cancerous 
[164]. In contrast, cancer stem cells can be 
derived from more differentiated cells that 
have undergone a mutation or epigenetic 
changes that give them stem cell properties 
[166]. It is believed that hypoxia promotes a 
generation of cancer stem cells. Some of the 
effects of hypoxia on the generation of cancer 
stem cells are mediated by the HIF proteins. It 
is striking that HIFs activate several key stem 
cell genes and pathways; thereby tumor 
hypoxia may contribute to the conversion of 
differentiated tumor cells into cancer stem 
cells [167]. It is interesting that two 
transcription factor markers for stem cells 
differentiation, Oct-4 and c-Myc, are directly 
activated by HIF- 2α. The activity of c-Myc, a 
prominent oncogene, is modulated by HIF. 
Through a binding to the transcription factor 
Sp1 under hypoxic conditions, HIF-1α 
antagonizes c-Myc activity and inhibits c-Myc 
dependent cell-cycle progression [168]. In 
contrast, HIF-2α potentiates c-Myc activity by 
enhancing its physical association with Sp1, 
Miz1, and Max [169]. Oct-4 transcription 
factor, which is not expressed in normal 
differentiated somatic cells, is also expressed 
in a variety of cancer cell lines and is induced 
by hypoxia in a HIF-2α expressing renal 
carcinoma cell line [170]. It has been 
demonstrated that inducible expressions of 
Oct-4 in transgenic mice produce reversible 
epithelial dysplasia, a characteristic of 
premalignant lesions [171]. Together, these 
data suggest that the Oct-4 locus, which is not 
expressed in normal differentiated somatic 
cells, may promote the proliferation of 
undifferentiated progenitor and/or stem cells, 
thereby contributing to tumor growth. 
However, it is not well-known to what extent 
Oct-4 contributes to the growth of human 
tumors. In addition, HIF regulation of ATP-
binding cassette (ABC) glycoprotein activity 
may also contribute to cancer stem cells 
formation. Some cancer stem cells express 
ABC glycoprotein transporters at the cell 
surface, a trait shared with normal 
hematopoietic stem cells. These transporters 
remove chemotherapeutic drugs and promote 
the multidrug resistance (MDR), observed in a 
large number of cancer cell lines [172]. 
Finally, HIFs have been shown to activate the 
Notch signaling pathway that controls stem 
cells self renewal and multipotency and 
appears to have both oncogenic and tumor 
suppressor effects in different contexts [173, 
174]. HIF-1α may also activate the expression 
of c-Myc by regulating Notch signaling [175]. 
These discoveries could help in developing 
novel therapeutics for cancer treatment.  The 
fact that cancer can grow from malignant cells 
with stem cell properties strongly support the 
idea that eradicating cancer stem cells should 
be an important goal in curing cancer.  
Therefore, the HIF pathways are even more 
attractive as targets of therapeutic intervention 
[156]. Inhibiting HIF activity could 
promotecancer stem cells differentiation, 
thereby reducing their ability to repopulate 
tumors after chemo and radiation therapies. 
 
5. DISCUSSION 
     Our understanding on the role of hypoxia in 
physiology and pathophysiology has increased 
several folds in recent years, thanks to 
identification of HIF which acts as a master 
regulator coordinating oxygen homeostasis.  
This review has summarized the current 
understanding of cell responses to chronic 
hypoxia and conditions in which hypoxia can 
be harmful or beneficial. Many questions need 
to be answered about how cells sense hypoxia 
and activate the oxygen-regulated pathways, 
and how the pathways are integrated. 
Significant studies are done to understand the 
hypoxia HIF-dependent responses, but limited 
researches available which have focused on 
the hypoxia HIF-independent responses. 
Despite the increase in knowledge of HIF 
activation, mechanisms that contribute to the 
positive and negative regulation of HIF are 
poorly understood. More research is required 
to determine the ratio of the pro-survival 
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pathways and cell death pathways that are 
activated in response to hypoxia and how these 
are regulated. A search in literature shows that 
hypoxia effects are analyzed under different 
conditions, such as cell types, duration of 
exposure to hypoxia, etc. It is well established 
that different cell or tissue types response 
differently to hypoxia. Therefore, the 
interpretations of the results in the literature 
are become more complicated. In order to 
obtain a unifying picture of hypoxia response a 
standardization of the experimental is needed. 
Finally, it is postulated that up to 5% of 
genome is transcriptionally regulated by 
hypoxia. Until identification of all these genes 
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